28186729|t|N-Terminal Hypothesis for Alzheimer's Disease
28186729|a|Although the amyloid (abeta peptide, Aβ) hypothesis is 25 years old, is the dominant model of Alzheimer's disease (AD) pathogenesis, and guides the development of potential treatments, it is still controversial. One possible reason is a lack of a mechanistic path from the cleavage products of the amyloid precursor protein (APP) such as soluble Aβ monomer and soluble molecular fragments to the deleterious effects on synaptic form and function. From a review of the recent literature and our own published work including aggregation kinetics and structural morphology, Aβ clearance, molecular simulations, long-term potentiation measurements with inhibition binding, and the binding of a commercial monoclonal antibody, aducanumab, we hypothesize that the N-terminal domains of neurotoxic Aβ oligomers are implicated in causing the disease.
28186729	0	10	N-Terminal	T087	C1706793
28186729	11	21	Hypothesis	T078	C1512571
28186729	26	45	Alzheimer's Disease	T047	C0002395
28186729	59	66	amyloid	T116,T123	C0002716
28186729	68	81	abeta peptide	T116	C0078939
28186729	83	85	Aβ	T116	C0078939
28186729	87	97	hypothesis	T078	C1512571
28186729	104	109	years	T079	C0439234
28186729	122	130	dominant	T169	C1527180
28186729	131	136	model	T170	C3161035
28186729	140	159	Alzheimer's disease	T047	C0002395
28186729	161	163	AD	T047	C0002395
28186729	165	177	pathogenesis	T046	C0699748
28186729	194	205	development	T169	C1527148
28186729	219	229	treatments	T061	C0087111
28186729	243	256	controversial	T054	C0680243
28186729	283	287	lack	T080	C0332268
28186729	293	309	mechanistic path	T169	C0441712
28186729	319	336	cleavage products	T167	C0439861
28186729	344	369	amyloid precursor protein	T116	C0085151
28186729	371	374	APP	T116	C0085151
28186729	384	391	soluble	T080	C1948047
28186729	392	402	Aβ monomer	T116	C3484390
28186729	415	424	molecular	T080	C1521991
28186729	425	434	fragments	T169	C0332255
28186729	442	461	deleterious effects	T080	C1280500
28186729	465	478	synaptic form	T042	C0597545
28186729	483	491	function	T169	C0542341
28186729	500	509	review of	T169	C0699752
28186729	521	531	literature	T170	C0023866
28186729	544	558	published work	T073,T170	C0034036
28186729	569	589	aggregation kinetics	T070	C0022702
28186729	594	604	structural	T082	C0678594
28186729	605	615	morphology	T080	C0332437
28186729	617	619	Aβ	T116	C0078939
28186729	620	629	clearance	T080	C0449297
28186729	631	640	molecular	T080	C1521991
28186729	641	652	simulations	T062	C0679083
28186729	654	676	long-term potentiation	T042	C0206249
28186729	677	689	measurements	T169	C0242485
28186729	695	713	inhibition binding	T044	C2259198
28186729	723	730	binding	T044	C1167622
28186729	747	766	monoclonal antibody	T116,T129	C0003250
28186729	768	778	aducanumab	T129	C4043101
28186729	783	794	hypothesize	T078	C1512571
28186729	804	822	N-terminal domains	T087	C1706793
28186729	826	836	neurotoxic	T131	C0260049
28186729	837	849	Aβ oligomers	T116	C0078939
28186729	868	875	causing	T169	C0678227
28186729	880	887	disease	T047	C0012634